comparemela.com

Page 9 - Ichnos Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Molecular Templates : 10-K/A Filing FY 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A . | April 28, 2023

United statesSan franciscoMenlo parkStanford universityFrance generalPatrickg enrightKevinm lalandeDavidr hoffmannJasons kimKevin lalandeMarkn lampertJonathan lanfearCorsee sandersEli lillyHarolde barry selickDavid hirsch

Global Dermatology Partnering 2016-2023: Deal Trends, Players and Financials

/PRNewswire/ The "Global Dermatology Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com s offering..

Nordrhein westfalenUnited kingdomUnited statesCase western reserve universityAlpha pharmaKaro pharmaGrupo ferrerDucere pharmaHill dermaceuticalsFalk pharmaBiophage pharmaAkaal pharmaChong kun dangAstellas pharmaBausch lombAngelini pharma

FDA news: Treatments for gastrointestinal, blood cancers receive orphan drug designations

The FDA announced several regulatory actions the past few weeks. Here is an overview of decisions that may be relevant to your practice.

United statesMindy valcarcelDeciphera pharmaceuticalsIchnos sciencesGenenta scienceEllipses pharmaOno pharma united states

ICHNOS SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR FIRST-IN-CLASS BISPECIFIC (CD38 x CD47) ANTIBODY INNATE CELL MODULATOR, ISB 1442

/PRNewswire/ Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific antibodies in oncology, today announced.

United statesNew yorkCyril kontoHead of communicationsPrnewswire ichnos sciences incIchnos sciencesDrug administrationEnd results programIchnos sciences incCorporate affairsSciences incChief executive officerMultiple myeloma awareness monthIchnos sciences inc

ICHNOS SCIENCES PRESENTS DATA SUPPORTING THREE ONCOLOGY ASSETS AT ASH 2022 ANNUAL MEETING

/PRNewswire/ Ichnos Sciences Inc., a global clinical-stage biotechnology company developing innovative multispecific immune cell engager antibodies in.

New yorkUnited statesTony jiangMario perroSanjay mohanCyril kontoStefano sammicheliAmerican society of hematologyHead of communicationsPrnewswire ichnos sciences incIchnos sciencesIchnos sciences incCorporate affairsOncology research at ichnos sciencesSciences incAmerican society

vimarsana © 2020. All Rights Reserved.